1410 related articles for article (PubMed ID: 28546007)
21. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
23. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
Xu X; Lu D; Ling Q; Wei X; Wu J; Zhou L; Yan S; Wu L; Geng L; Ke Q; Gao F; Tu Z; Wang W; Zhang M; Shen Y; Xie H; Jiang W; Wang H; Zheng S
Gut; 2016 Jun; 65(6):1035-41. PubMed ID: 25804634
[TBL] [Abstract][Full Text] [Related]
24. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.
Parfitt JR; Marotta P; Alghamdi M; Wall W; Khakhar A; Suskin NG; Quan D; McAllister V; Ghent C; Levstik M; McLean C; Chakrabarti S; Garcia B; Driman DK
Liver Transpl; 2007 Apr; 13(4):543-51. PubMed ID: 17394152
[TBL] [Abstract][Full Text] [Related]
25. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
26. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
27. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
28. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
Zavaglia C; De Carlis L; Alberti AB; Minola E; Belli LS; Slim AO; Airoldi A; Giacomoni A; Rondinara G; Tinelli C; Forti D; Pinzello G
Am J Gastroenterol; 2005 Dec; 100(12):2708-16. PubMed ID: 16393224
[TBL] [Abstract][Full Text] [Related]
29. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
30. Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience.
Wehrle CJ; Raj R; Maspero M; Satish S; Eghtesad B; Pita A; Kim J; Khalil M; Calderon E; Orabi D; Zervos B; Modaresi Esfeh J; Whitsett Linganna M; Diago-Uso T; Fujiki M; Quintini C; Kwon CD; Miller C; Pinna A; Aucejo F; Hashimoto K; Schlegel A
Int J Surg; 2024 May; 110(5):2818-2831. PubMed ID: 38241354
[TBL] [Abstract][Full Text] [Related]
31. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
[TBL] [Abstract][Full Text] [Related]
33. Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.
Shen J; Yeh CC; Wang Q; Gurvich I; Siegel AB; Santella RM
Anticancer Res; 2016 Oct; 36(10):5307-5314. PubMed ID: 27798893
[TBL] [Abstract][Full Text] [Related]
34. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
35. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
36. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
[TBL] [Abstract][Full Text] [Related]
37. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
Mahmud N; John B; Taddei TH; Goldberg DS
Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
[TBL] [Abstract][Full Text] [Related]
38. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
[TBL] [Abstract][Full Text] [Related]
39. Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation.
Lv Z; Cai X; Weng X; Xiao H; Du C; Cheng J; Zhou L; Xie H; Sun K; Wu J; Zheng S
Surgery; 2015 Jul; 158(1):142-50. PubMed ID: 25890776
[TBL] [Abstract][Full Text] [Related]
40. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era.
Devaki P; Wong RJ; Marupakula V; Nangia S; Nguyen L; Ditah IC; Ehrinpreis MN; Nguyen MH
Cancer; 2014 Jun; 120(11):1725-32. PubMed ID: 24590359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
